Invivyd (NASDAQ:IVVD) Receives Buy Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note released on Thursday,Benzinga reports. BTIG Research currently has a $10.00 price objective on the stock.

A number of other research analysts have also commented on IVVD. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, HC Wainwright upped their price objective on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Price Performance

Invivyd stock opened at $1.70 on Thursday. The company has a market capitalization of $396.30 million, a price-to-earnings ratio of -3.62 and a beta of 0.60. Invivyd has a one year low of $0.46 and a one year high of $3.07. The company’s fifty day moving average price is $2.11 and its two-hundred day moving average price is $1.78.

Insider Buying and Selling at Invivyd

In other Invivyd news, insider Timothy Edward Lee sold 20,964 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the sale, the insider directly owned 117,717 shares in the company, valued at $185,992.86. This trade represents a 15.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jill Andersen sold 34,939 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $55,203.62. Following the transaction, the insider directly owned 181,736 shares of the company’s stock, valued at $287,142.88. This represents a 16.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 227,172 shares of company stock valued at $354,534 in the last three months. 25.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Invivyd

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Courier Capital LLC acquired a new position in Invivyd in the 4th quarter valued at approximately $25,000. Bronte Capital Management Pty Ltd. bought a new stake in shares of Invivyd during the fourth quarter valued at approximately $27,000. DRW Securities LLC bought a new stake in shares of Invivyd during the fourth quarter valued at approximately $27,000. ProShare Advisors LLC acquired a new position in shares of Invivyd in the fourth quarter valued at $30,000. Finally, State of Wyoming bought a new position in Invivyd in the fourth quarter worth $30,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.